National agency announces $100M in funding for energy advancement at Houston event

seeing green

At Houston event, the Department of Energy’s Advanced Research Projects Agency-Energy announced $100 million in cleantech funding. Photos by Jeff Fitlow/Rice University

Rice University played host to the first-of-its-kind event from the Department of Energy’s Advanced Research Projects Agency-Energy, or ARPA-E, earlier this month in which the governmental agency announced $100 million in funding for its SCALEUP program.

Dubbed “ARPA-E on the Road: Houston,” the event welcomed more than 100 energy innovators to the Hudspeth Auditorium in Rice’s Anderson-Clarke Center on June 8. Evelyn Wang, director of ARPA-E, announced the funding, which represents the third installment from the agency for its program SCALEUP, or Seeding Critical Advances for Leading Energy technologies with Untapped Potential, which supports the commercialization of clean energy technology.

The funding is awarded to previous ARPA-E awardees with a "viable road to market" and "ability to attract private sector investments," according to a statement from the Department of Energy. Previous funding was granted in 2019 and 2021.

"ARPA-E’s SCALEUP program has successfully demonstrated what can happen when technical experts are empowered with the commercialization support to develop a strong pathway to market” Wang said. “I’m excited that we are building on the success of this effort with the third installment of SCALEUP, and I look forward to what the third cohort of teams accomplish.”

Rice Vice President for Research Ramamoorthy Ramesh also spoke at the event on how Rice is working to make Houston a leader in energy innovation. Joe Zhou, CEO of Houston-based Quidnet Energy, also spoke on a panel about how ARPA-E funding benefited his company along with Oregon-based Onboard Dynamics’s CEO Rita Hansen and Massachusetts-based Quaise Energy’s CEO Carlos Araque.

Attendees were able to ask questions to Wang and ARPA-E program directors about the agency’s funding approach and other topics at the event.

Houston energy innovators have benefited from programs like SCALEUP.

Quidnet Energy received $10 million in funding from ARPA-E as part of its SCALEUP program in 2022. The company's technology can store renewable energy for long periods of time in large quantities.

In January, Houston-based Zeta Energy also announced that it has secured funding from ARPA-E. The $4 million in funding came from the agency's Electric Vehicles for American Low-Carbon Living, or EVs4ALL, program. Zeta Energy is known for its lithium sulfur batteries

------

This article originally ran on EnergyCapital.

From Your Site Articles
Houston-based Quidnet Energy has secured funding from a Department of Energy program. Image via quidnetenergy.com

Houston energy storage startup secures $10M in federal funding

seeing green

A Houston-based company that's got a solution to renewable energy storage has just secured funding from a federal entity.

The U.S. Department of Energy Advanced Research Projects Agency-Energy, or ARPA-E, is granting Quidnet Energy $10 million in funding, the Houston company announced this week. The funding is a part of the ARPA-E Seeding Critical Advances for Leading Energy technologies with Untapped Potential, the SCALEUP program. This initiative is aimed at providing funding to previous ARPA-E teams "that have been determined to be feasible for widespread deployment and commercialization domestically," per a news release.

“We’re honored that ARPA-E has selected Quidnet Energy as an awardee of the SCALEUP program,” says Joe Zhou, CEO of Quidnet Energy, in the release. “This funding will support continued work on our Geomechanical Pumped Storage (GPS) project with CPS Energy, which will demonstrate the benefits of using proven pumped hydro technology to create a long-duration energy storage resource that doesn’t require mountainous terrain. We look forward to continuing our partnership with CPS Energy and thank ARPA-E for acknowledging the potential of GPS for long-duration storage.”

The company's technology can store renewable energy for long periods of time in large quantities. The process includes storing pressurized water underground and, when the stored energy is needed, the water propels hydroelectric turbines and produces the electricity to support the grid at a fraction of the cost, per the news release. The concept is similar to existing gravity-powered pumped storage, but with less land required.

The fresh funding will be used toward Quidnet Energy’s ongoing project with San Antonio-based utilitary provider CPS Energy. This collaboration is scaling the company's GPS to a 1 MW/10 MWh commercial system, per the release, that will provide CPS Energy with over 10 hour long-duration energy storage system.

In 2020, Quidnet closed its $10 million series B financing round and secured a major contract with the New York State Energy Development Authority. The series B round included participation from Bill Gates-backed Breakthrough Energy Ventures and Canada-based Evok Innovations, which both previously invested in the company, as well as new investors Trafigura and The Jeremy and Hannelore Grantham Environmental Trust.

Houston-based Quidnet Energy has closed a $10 million series B round and secured a big contract with the state of New York. Getty Images

Houston renewable energy company closes $10M series B

Money moves

Houston-based renewable energy company that focuses on clean energy storage closed its $10 million series B financing round and secured a major contract.

Quidnet Energy announced its latest round and the execution of a contract with the New York State Energy Development Authority. Bill Gates-backed Breakthrough Energy Ventures and Canada-based Evok Innovations, which both previously invested in the company, contributed to the round. The round also featured new investors Trafigura and The Jeremy and Hannelore Grantham Environmental Trust.

"Long-duration electricity storage is critical to the energy transition. It's exciting to see how Quidnet is bringing this viable long-duration solution to the market," says Mike Biddle, managing director at Evok Innovations, in a news release. "Because they are leveraging long understood geologic principles, we are confident that they can scale rapidly. We are pleased to support the Quidnet team through its next phase of commercial growth."

According to the release, the company will use the funds to grow its team and scale up its operations in order to be able to deliver commercial-scale projects across the country's electric grid.

"Integrating renewables and replacing retiring thermal generation require cost-effective long-duration electricity storage at an immense scale," says Quidnet Energy CEO Joe Zhou in the release. "While traditional pumped hydro has provided over 95 percent of the world's grid-scale storage, that approach faces significant siting and cost limitations going forward. Quidnet unlocks these constraints to fundamentally change the economics and deployment profile of long-duration storage."

Quidnet's deal with NYSEDA is a part of the organization's efforts to reduce the state's carbon footprint while also lowering the cost of traditional energy storage.

"Under Governor Cuomo's leadership, New York is investing in the technology research and development needed to advance a 21st electric grid that can support the State's growing influx of renewable energy," says Alicia Barton, president and CEO of NYSERDA, in the release. "Congratulations to Quidnet on this opportunity to develop and demonstrate the value that this innovative technology can bring to New York as we work to reduce greenhouse gas emissions and transition to a 100 percent clean electric grid."

Last month, the Rice Alliance for Technology and Entrepreneurship hosted its annual Energy Tech Venture Day online, and Quidnet was among the Houston energy companies to pitch virtually.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Houston digital health platform Koda lands strategic investment

money moves

Houston-based advance care planning platform Koda Health has added another investor to the lineup.

The company secured a strategic investment for an undisclosed amount from UPMC Enterprises, the commercialization arm of the University of Pittsburgh Medical Center. The funding is part of Koda's oversubscribed series A funding round that closed in October, according to a release.

"UPMC Enterprises’ investment is a meaningful signal, not just to Koda, but to the broader market," Dr. Desh Mohan, chief medical officer and co-founder of Koda Health, said in the news release. "It validates that health systems are ready to invest in infrastructure that makes advance care planning work the way it should: proactively, at scale, and with the human support that these conversations require. Having UPMC Enterprises as a strategic investor puts us in a unique position to prove what's possible."

Koda has raised $14 million to date, according to a representative from the company. Its series A round was led by Evidenced, with participation from Mudita Venture Partners, Techstars and the Texas Medical Center last year. At the time, the company said the funding would allow it to scale operations and expand engineering, clinical strategy and customer success. The company described the round as a "pivotal moment," as it had secured investments from influential leaders in the healthcare and venture capital space.

Koda Health, which was born out of the TMC's Biodesign Fellowship in 2020, saw major growth last year, as well, and now supports more than 1 million patients nationwide through partnerships with Cigna Healthcare, Privia Health, Guidehealth, Sentara, UPMC and Memorial Hermann Health System.

The company integrated its end-of-life care planning platform with Dallas-based Guidehealth in April 2025 and with Epic Systems in July 2025. It also won the 2025 Houston Innovation Award in the Health Tech Business category. Read more here.

UH med school gets $2M gift and more top Houston innovation news

Trending Topics

Editor's note: The top Houston innovation news of the month is full of fresh funding, with two Texas medical schools receiving major gifts — one of historic proportions. Below are the five most-read InnovationMap headlines from April 16-30, 2026.

UH med school granted $2M gift to offer student scholarships

A new scholarship endowment aims to support students in the University of Houston’s recently established medical school. The University of Houston’s Tilman J. Fertitta Family College of Medicine received a planned estate gift commitment estimated at $2.1 million to establish the Bob Diehl and Teresa Evans Diehl Scholarship Endowment. The scholarship will assist full-time medical students who demonstrate financial need and meet academic standards. Continue reading.

How Houston innovators played a role in the historic Artemis II splashdown

Research from Rice University played a critical role in the safe return of U.S. astronauts aboard NASA’s Artemis II mission this month. Rice mechanical engineer Tayfun E. Tezduyar and longtime collaborator Kenji Takizawa developed a key computational parachute fluid-structure interaction (FSI) analysis system that proved vital in NASA’s Orion capsule’s descent into the Pacific Ocean. The FSI system, originally developed in 2013 alongside NASA Johnson Space Center, was critical in Orion’s three-parachute design, which slowed the capsule as it returned to Earth, according to Rice. Continue reading.

Baylor scientist lands $2M grant to explore links between viruses and Alzheimer’s

A Baylor College of Medicine scientist will begin exploring the possible link between Alzheimer’s disease and viral infections thanks to a $2 million grant awarded in March. Dr. Ryan S. Dhindsa hypothesizes that Alzheimer’s may have some link to previous viral infections contracted by the patient. To study this intriguing possibility, the American Brain Foundation has gifted him the Cure One, Cure Many award in neuroinflammation. Continue reading.

New UT Austin med center, anchored by MD Anderson, gets historic gift

A donation announced April 21 breaks a major record at the University of Texas at Austin. Michael and Susan Dell are now UT Austin's first supporters to give $1 billion. In response, the university will create the UT Dell Campus for Advanced Research and the UT Dell Medical Center to "advance human health," per a press release. Continue reading.

Houston VC funding surged nearly 50% in Q1 2026, report says

Houston saw a jump in VC funding in Q1 2026, fueled by several major investments in clean energy startups. Image via Getty Images

First-quarter venture capital funding for Houston-area startups climbed nearly 50 percent compared to the same time last year, according to the PitchBook-NVCA Venture Monitor. In Q1 2026, Houston-area startups raised $532.3 million, a 49 percent jump from $320.2 million in Q1 2025, according to the PitchBook-NVCA Venture Monitor. However, the Q1 total fell 23 percent from the $671.05 million raised in Q4 2025. Continue reading.

New 'living pharmacy' biotech company launches out of Rice venture studio

fighting cancer

Rice University’s biotech venture studio RBL LLC has launched a new “living pharmacy” company, Duracyte, designed to make cancer treatment easier on patients.

Backed by an up to $45 million Advanced Research Projects Agency for Health (ARPA-H) award, Duracyte aims to commercialize implantable biohybrid pharmacy devices that are designed to produce therapeutic proteins inside the human body around the clock, replacing the need for regular injections and infusions for some cancer patients.

The company’s main platform is its Hybrid Advanced Molecular Manufacturing Regulator (HAMMR), a rechargeable, implantable device that can sense biological signals, monitor tumor environments and adjust therapeutic output in real time. HAMMR has wireless communication capabilities, which allow patients and clinicians to remotely monitor results through an app every five minutes and make changes to treatment plans without a hosptial visit. Additionally, the device can generate its own oxygen supply, which is key for the therapeutic cells’ survival.

“Biologic medicines such as monoclonal antibodies, cytokines and metabolic regulators already account for a significant share of modern therapeutics, but the way we deliver them today often requires frequent injections or infusions that can be demanding for patients and lead to inconsistent drug levels,” Daniel Anderson, MIT professor and co-founder of Duracyte, said in a news release. “Our vision is to enable a continuous, stable therapy by producing these medicines directly inside the body, which could improve treatment consistency, reduce side effects and ultimately transform how biologic therapies are delivered across many diseases.”

Duracyte’s first clinical trial is slated to begin by the end of 2026 and will focus on recurrent ovarian cancer. The Phase I study will build upon existing work on encapsulated cytokine pharmacy technology, and the company hopes that within a few years this treatment can reach clinical application.

The development of Duracyte is supported by ARPA-H's Targeted Hybrid Oncotherapeutic Regulation (THOR) project, which supports a multidisciplinary research consortium co-led by Omid Veiseh, a professor of bioengineering at Rice. The consortium also includes others at Rice, The University of Texas MD Anderson Cancer Center, Stanford University, Carnegie Mellon University, Northwestern University and the University of Houston, plus industry collaborators like Chicago-based CellTrans.

“What we are building is the culmination of years of progress in cell engineering, biomaterials and implantable device technology,” Veiseh added in the release. “By combining these advances with real-time sensing and adaptive drug delivery, we are working with the support of RBL to create a true ‘living pharmacy’ that can deliver continuous, precisely controlled biologic therapies and fundamentally change how these treatments reach patients.”

RBL launched in 2024 and is based out of Houston’s Texas Medical Center Helix Park. Duracyte is the third company launched by RBL, including Sentinel BioTherapeutics, a clinical-stage immunotherapy company developing localized cytokine therapies for solid tumors, and SteerBio, a regenerative medicine company targeting lymphedema.

“Duracyte exemplifies the kind of breakthrough that Houston’s ecosystem is built to produce,” Paul Wotton, managing partner of RBL LLC and co-founder of Duracyte, added in the release. “With world-class clinical infrastructure, exceptional engineering talent and initiatives like the Texas Biotech Task Force driving alignment across industry, investment and talent, this region is uniquely positioned to move the most ambitious ideas in medicine from concept to patient, faster than anywhere else.”

View All Listings